Project: Recommendations on Treatment of Rheumatoid Arthritis Developed by All-Russian Public Organization «association of Rheumatologists of Russia» – 2014 (Part 1)

Насонов, Е. Л.; Mazurov, V. I.; Каратеев, Д. Е.; Lukina, G. V.; Zhilyaev, E. V.; Amirdzhanova, V. N.; Muraviyov, Yu. V.; Tchichasova, N. V.

doi:10.14412/1995-4484-2015-1-17

Cited by 11 publications

(3 citation statements)

References 113 publications

(128 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Опубликованная в научной печати версия рекоменда-ций общероссийской общественной организации «Ассо-циация ревматологов России» (АРР) по лечению РА [30,31] позиционирует ТОФА как преимущественно препарат 3-го ряда, рекомендуя его назначение при недостаточном отве-те на ингибиторы фактора некроза опухоли альфа (и-ФНО-α). Подобный взгляд на роль ТОФА сохраняется в целом в последней версии рекомендаций, представлен-ной в 2017 г.…”

Section: позиционирование тофацитиниба в стратегии лечения ревматоиднunclassified

Russian and International Experience in the Application of the Janus-Kinases Inhibitor in Rheumatoid Arthritis

2017

Self Cite

View full text Add to dashboard Cite

Section: позиционирование тофацитиниба в стратегии лечения ревматоиднunclassified

Russian and International Experience in the Application of the Janus-Kinases Inhibitor in Rheumatoid Arthritis

2017

Self Cite

View full text Add to dashboard Cite

“…Высокая распространенность заболеваний сер-дечно-сосудистой системы у больных РА диктует необходимость привлечения специалистов кардиоло-гического профиля при консультативной поддержке врачей -ревматологов в лечении данной категории пациентов, что отражено в Проекте рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации "Ассоциация ревматоло-гов России" -2014 (часть 1) [11]. В соответствии с рекомендациями, мультидисциплинарный подход к ведению пациентов с РА позволяет снизить нега-тивное влияние коморбидной патологии на течение и прогноз заболевания [11].…”

unclassified

“…В соответствии с рекомендациями, мультидисциплинарный подход к ведению пациентов с РА позволяет снизить нега-тивное влияние коморбидной патологии на течение и прогноз заболевания [11].…”

unclassified

Evaluation of Cardiovascular Risk Factors in Patients With Rheumatoid Arthritis

Стародубцева¹,

Vasilieva²

2016

Russ J Cardiol

View full text Add to dashboard Cite

Clinical aspects of the use of etanercept in treatment of rheumatoid arthritis.

2018

View full text Add to dashboard Cite

Background. Maintaining of a favourable response of tumour necrosis factor inhibitors is one of the most challenging to rheumatologist. Only limited data have been published addressing this field. The aim of our study was investigate efficacy of etanercept (ETN) and evaluate maintaining response after ETN discontinuation in patients who have achieved remission or low disease activity (REM/LDA) of rheumatoid arthritis (RA). Methods. Patients with high disease activity (n = 29) received ETN 50 mg injection and methotrexate 10-20 mg once weekly were included in analysis. Frequency of REM/LDA scoring by DAS 28-joint counts and C-reactive protein level (DAS28-CRP), changes from baseline in DAS28-CRP, Health Assessment Questionnaire (HAQ), global assessment of disease activity by patient and provider (PtGA and PrGA) were evaluated. We assessed persistent of achieved REM/LDA after the ETN discontinued. Results. We saw fast decreasing of active flare already after first month: HAQ (1.4 ± 0.6 vs 2.0 ± 0.6, p = 0.048), PtGA (49.5 ± 17.9 vs 75.6 ± 14.9, p = 0.016) and PrGA (46.6 ± 14.7 vs 77.0 ± 12.3, p = 0.014). DAS28-CRP changes from baseline become significant after second month (3.9 ± 1.1 vs 6.2 ± 0.6, р = 0.005). After 6 months 82.6% patients had DAS28-CRP < 3.2 and 41.4% patients had HAQ < 0.5. Maintenance of REM/LDA lasted 3 month after ETN discontinuation. Conclusion. ETN+MTX is very effective combination in treat to target strategy of RA treatment. In patients who have achieved REM/LDA maintained stable condition during three months after ETN withdrawn. It might be consider in a number of patients in case of accidental or necessary treatment interruption.

show abstract

Project: Recommendations on Treatment of Rheumatoid Arthritis Developed by All-Russian Public Organization «association of Rheumatologists of Russia» – 2014 (Part 1)

Cited by 11 publications

References 113 publications

Russian and International Experience in the Application of the Janus-Kinases Inhibitor in Rheumatoid Arthritis

Russian and International Experience in the Application of the Janus-Kinases Inhibitor in Rheumatoid Arthritis

Evaluation of Cardiovascular Risk Factors in Patients With Rheumatoid Arthritis

Clinical aspects of the use of etanercept in treatment of rheumatoid arthritis.

Contact Info

Product

Resources

About